A new vaccination program is being rolled out across England, Wales, and Northern Ireland to protect newborns and older adults from Respiratory Syncytial Virus (RSV). This follows a similar launch in Scotland. RSV is a common winter virus. It causes coughs and colds but can also lead to severe and potentially life-threatening respiratory issues. For the first time, the vaccine will be offered to pregnant women who are 28 weeks or more. It will also be available to elderly individuals aged 75 to 79.
Each year in England, around 20,000 babies are hospitalised due to RSV-related illnesses, with up to 30 fatalities. The virus is a leading cause of chest problems, such as bronchiolitis, in young children and contributes to thousands of pneumonia cases among the elderly. Medical experts stress the importance of vaccination, particularly for vulnerable infants, including those born prematurely or with existing health conditions.
The vaccine, called Abrysvo and developed by Pfizer, has shown significant effectiveness in reducing severe lung infections in infants during their first six months, lowering the risk by about 70%. Research indicates that this vaccination program could prevent thousands of hospitalisations and ease the burden on healthcare services during the winter months.
Health professionals are urging eligible groups, especially pregnant women, to get vaccinated. They believe this initiative could make a substantial difference in reducing RSV-related complications and pressures on emergency services this winter.
